<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240704160945&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20240704160945&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 04 Jul 2024 20:09:48 +0000</lastbuilddate>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 4. doi: 10.1161/CIRCRESAHA.123.323819. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: How the sarcomeric complex is continuously turned over in long-living cardiomyocytes is unclear. According to the prevailing model of sarcomere maintenance, sarcomeres are maintained by cytoplasmic soluble protein pools with free recycling between pools and sarcomeres.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We imaged and quantified the turnover of expressed and endogenous sarcomeric proteins, including the giant protein titin, in cardiomyocytes in culture and in vivo, at the single cell and at the single sarcomere level using pulse-chase labeling of Halo-tagged proteins with covalent ligands.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We disprove the prevailing protein pool model and instead show an ordered mechanism in which only newly translated proteins enter the sarcomeric complex while older ones are removed and degraded. We also show that degradation is independent of protein age and that proteolytic extraction is a rate-limiting step in the turnover. We show that replacement of sarcomeric proteins occurs at a similar rate within cells and across the heart and is slower in adult cells.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings establish a unidirectional replacement model for cardiac sarcomeres subunit replacement and identify their turnover principles.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38962864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38962864</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323819>10.1161/CIRCRESAHA.123.323819</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38962864</guid>
<pubDate>Thu, 04 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Guy Douvdevany</dc:creator>
<dc:creator>Itai Erlich</dc:creator>
<dc:creator>Lilac Haimovich-Caspi</dc:creator>
<dc:creator>Tomer Mashiah</dc:creator>
<dc:creator>Maksymilian Prondzynski</dc:creator>
<dc:creator>Maria Rosaria Pricolo</dc:creator>
<dc:creator>Jorge Alegre-Cebollada</dc:creator>
<dc:creator>Wolfgang A Linke</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Izhak Kehat</dc:creator>
<dc:date>2024-07-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Imaging of Existing and Newly Translated Proteins Elucidates Mechanisms of Sarcomere Turnover</dc:title>
<dc:identifier>pmid:38962864</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323819</dc:identifier>
</item>
<item>
<title>An Intramyocardial Mass Mimicking ST-Segment Elevation Myocardial Infarct at Presentation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>ST-segment elevation on the electrocardiogram typically indicates acute myocardial infarction but can mimic ST-segment elevation myocardial infarction in various conditions. We present a case of a patient with an intramyocardial mass and anterior ST-segment elevation without significant myocardial biomarker elevation. Multimodality imaging was crucial in revealing cardiac metastasis as the attributable cause.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):229-231. doi: 10.1016/j.jacc.2024.05.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">ST-segment elevation on the electrocardiogram typically indicates acute myocardial infarction but can mimic ST-segment elevation myocardial infarction in various conditions. We present a case of a patient with an intramyocardial mass and anterior ST-segment elevation without significant myocardial biomarker elevation. Multimodality imaging was crucial in revealing cardiac metastasis as the attributable cause.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960518</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.012>10.1016/j.jacc.2024.05.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960518</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Mariana Ferreira Carvalho</dc:creator>
<dc:creator>Margarida Cabral</dc:creator>
<dc:creator>Carolina Gonçalves</dc:creator>
<dc:creator>Luís Graça Santos</dc:creator>
<dc:creator>João Morais</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>An Intramyocardial Mass Mimicking ST-Segment Elevation Myocardial Infarct at Presentation</dc:title>
<dc:identifier>pmid:38960518</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.012</dc:identifier>
</item>
<item>
<title>Insights From Midcareer Women in Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):219-222. doi: 10.1016/j.jacc.2024.04.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960517</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.049>10.1016/j.jacc.2024.04.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960517</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Kamala P Tamirisa</dc:creator>
<dc:creator>Modele O Ogunniyi</dc:creator>
<dc:creator>Ming Hui Chen</dc:creator>
<dc:creator>Johanna Contreras</dc:creator>
<dc:creator>Ann T Tong</dc:creator>
<dc:creator>Madhavi Kadiyala</dc:creator>
<dc:creator>Jennifer A Tremmel</dc:creator>
<dc:creator>J Jane Cao</dc:creator>
<dc:creator>Nausheen Akhter</dc:creator>
<dc:creator>Sandra J Lewis</dc:creator>
<dc:creator>ACC’s Sandra J. Lewis Mid-Career Leadership Inaugural Cohort</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Insights From Midcareer Women in Cardiology</dc:title>
<dc:identifier>pmid:38960517</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.049</dc:identifier>
</item>
<item>
<title>Understanding JACC's Initial Submission Review: Rapid, Thorough, Fair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):216-218. doi: 10.1016/j.jacc.2024.05.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960516</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.035>10.1016/j.jacc.2024.05.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960516</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Understanding JACC's Initial Submission Review: Rapid, Thorough, Fair</dc:title>
<dc:identifier>pmid:38960516</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.035</dc:identifier>
</item>
<item>
<title>Team-Driven Quality Improvement: The Key to Transforming Heart Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):213-215. doi: 10.1016/j.jacc.2024.05.025.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960515</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.025>10.1016/j.jacc.2024.05.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960515</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:creator>Andrea Price</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Team-Driven Quality Improvement: The Key to Transforming Heart Health</dc:title>
<dc:identifier>pmid:38960515</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.025</dc:identifier>
</item>
<item>
<title>Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):195-212. doi: 10.1016/j.jacc.2024.04.047.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and mortality. Important risk factors for the development of HFpEF are similar to risk factors for the progression of tricuspid regurgitation (TR), and both conditions frequently coexist and thus is a distinct phenotype or a marker for advanced HF. Many patients with severe, symptomatic atrial secondary TR have been enrolled in current transcatheter device trials, and may represent patients at an advanced stage of HFpEF. Management of HFpEF thus may affect the pathophysiology of TR, and the physiologic changes that occur following transcatheter treatment of TR, may also impact symptoms and outcomes in patients with HFpEF. This review discusses these issues and suggests possible management strategies for these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960514</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.047>10.1016/j.jacc.2024.04.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960514</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Frank Edelmann</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Philip Lurz</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tricuspid Regurgitation in Patients With Heart Failure and Preserved Ejection Fraction: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38960514</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.047</dc:identifier>
</item>
<item>
<title>Sex Differences, Graft Failure, and Mortality: An Ounce of Prevention After the Pound of Cure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):192-194. doi: 10.1016/j.jacc.2024.05.008.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960513</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.008>10.1016/j.jacc.2024.05.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960513</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy A Sarma</dc:creator>
<dc:creator>Jared A Spitz</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Sex Differences, Graft Failure, and Mortality: An Ounce of Prevention After the Pound of Cure</dc:title>
<dc:identifier>pmid:38960513</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.008</dc:identifier>
</item>
<item>
<title>Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Graft failure is more frequent in women and is associated with adverse cardiac events. The excess mortality risk associated with female sex among CABG patients is not mediated by graft failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):182-191. doi: 10.1016/j.jacc.2024.04.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women have worse outcomes after coronary artery bypass surgery (CABG) than men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to determine the incidence of CABG graft failure in women, its association with cardiac events, and whether it contributes to sex-related differences in outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A pooled analysis of individual patient data from randomized clinical trials with systematic imaging follow-up was performed. Multivariable logistic regression models were used to assess the association of graft failure with myocardial infarction and repeat revascularization between CABG and imaging (primary outcome) and death after imaging (secondary outcome). Mediation analysis was performed to evaluate the effect of graft failure on the association between female sex and risk of death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Seven randomized clinical trials (N = 4,413, 777 women) were included. At a median imaging follow-up of 1.03 years, graft failure was significantly more frequent among women than men (37.3% vs 32.9% at the patient-level and 20.5% vs 15.8% at the graft level; P = 0.02 and P &lt; 0.001, respectively). In women, graft failure was associated with an increased risk of myocardial infarction and repeat revascularization (OR: 3.94; 95% CI: 1.79-8.67) and death (OR: 3.18; 95% CI: 1.73-5.85). Female sex was independently associated with the risk of death (direct effect, HR: 1.84; 95% CI: 1.35-2.50) but the association was not mediated by graft failure (indirect effect, HR: 1.04; 95% CI: 0.86-1.26).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Graft failure is more frequent in women and is associated with adverse cardiac events. The excess mortality risk associated with female sex among CABG patients is not mediated by graft failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960512</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.046>10.1016/j.jacc.2024.04.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960512</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Kevin R An</dc:creator>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Rachel Heise</dc:creator>
<dc:creator>Antonino Di Franco</dc:creator>
<dc:creator>Stephen E Fremes</dc:creator>
<dc:creator>David L Hare</dc:creator>
<dc:creator>Alexander Kulik</dc:creator>
<dc:creator>Andre Lamy</dc:creator>
<dc:creator>Joyce Peper</dc:creator>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>Jurrien M Ten Berg</dc:creator>
<dc:creator>Laura M Willemsen</dc:creator>
<dc:creator>Qiang Zhao</dc:creator>
<dc:creator>Yunpeng Zhu</dc:creator>
<dc:creator>Daniel M Wojdyla</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications</dc:title>
<dc:identifier>pmid:38960512</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.046</dc:identifier>
</item>
<item>
<title>In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):178-181. doi: 10.1016/j.jacc.2024.05.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960511</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.009>10.1016/j.jacc.2024.05.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960511</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Sotirios Tsimikas</dc:creator>
<dc:creator>Calvin Yeang</dc:creator>
<dc:creator>Florian Kronenberg</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes</dc:title>
<dc:identifier>pmid:38960511</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.009</dc:identifier>
</item>
<item>
<title>Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol- or Apolipoprotein B-Related Risk of Coronary Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Correction of LDL-C for its Lp(a)-C content provided no meaningful information on CHD-risk estimation at the population level. Simple categorization of Lp(a) mass (≥/&lt;90th percentile) influenced the association between LDL-C or apoB with future CHD mostly at higher Lp(a) levels.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):165-177. doi: 10.1016/j.jacc.2024.04.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Conventional low-density lipoprotein cholesterol (LDL-C) quantification includes cholesterol attributable to lipoprotein(a) (Lp(a)-C) due to their overlapping densities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purposes of this study were to compare the association between LDL-C and LDL-C corrected for Lp(a)-C (LDL<sub>Lp(a)corr</sub>) with incident coronary heart disease (CHD) in the general population and to investigate whether concomitant Lp(a) values influence the association of LDL-C or apolipoprotein B (apoB) with coronary events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 68,748 CHD-free subjects at baseline LDL<sub>Lp(a)corr</sub> was calculated as "LDL-C-Lp(a)-C," where Lp(a)-C was 30% or 17.3% of total Lp(a) mass. Fine and Gray competing risk-adjusted models were applied for the association between the outcome incident CHD and: 1) LDL-C and LDL<sub>Lp(a)corr</sub> in the total sample; and 2) LDL-C and apoB after stratification by Lp(a) mass (≥/&lt;90th percentile).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Similar risk estimates for incident CHD were found for LDL-C and LDL-C<sub>Lp(a)corr30</sub> or LDL-C<sub>Lp(a)corr17.3</sub> (subdistribution HR with 95% CI) were 2.73 (95% CI: 2.34-3.20) vs 2.51 (95% CI: 2.15-2.93) vs 2.64 (95% CI: 2.26-3.10), respectively (top vs bottom fifth; fully adjusted models). Categorization by Lp(a) mass resulted in higher subdistribution HRs for uncorrected LDL-C and incident CHD at Lp(a) ≥90th percentile (4.38 [95% CI: 2.08-9.22]) vs 2.60 [95% CI: 2.21-3.07]) at Lp(a) &lt;90th percentile (top vs bottom fifth; P<sub>interaction</sub>0.39). In contrast, apoB risk estimates were lower in subjects with higher Lp(a) mass (2.43 [95% CI: 1.34-4.40]) than in Lp(a) &lt;90th percentile (3.34 [95% CI: 2.78-4.01]) (P<sub>interaction</sub>0.49).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Correction of LDL-C for its Lp(a)-C content provided no meaningful information on CHD-risk estimation at the population level. Simple categorization of Lp(a) mass (≥/&lt;90th percentile) influenced the association between LDL-C or apoB with future CHD mostly at higher Lp(a) levels.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960510</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.050>10.1016/j.jacc.2024.04.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960510</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Natalie Arnold</dc:creator>
<dc:creator>Christopher Blaum</dc:creator>
<dc:creator>Alina Goßling</dc:creator>
<dc:creator>Fabian J Brunner</dc:creator>
<dc:creator>Benjamin Bay</dc:creator>
<dc:creator>Tanja Zeller</dc:creator>
<dc:creator>Marco M Ferrario</dc:creator>
<dc:creator>Paolo Brambilla</dc:creator>
<dc:creator>Giancarlo Cesana</dc:creator>
<dc:creator>Valerio Leoni</dc:creator>
<dc:creator>Luigi Palmieri</dc:creator>
<dc:creator>Chiara Donfrancesco</dc:creator>
<dc:creator>Francisco Ojeda</dc:creator>
<dc:creator>Allan Linneberg</dc:creator>
<dc:creator>Stefan Söderberg</dc:creator>
<dc:creator>Licia Iacoviello</dc:creator>
<dc:creator>Francesco Gianfagna</dc:creator>
<dc:creator>Simona Costanzo</dc:creator>
<dc:creator>Susana Sans</dc:creator>
<dc:creator>Giovanni Veronesi</dc:creator>
<dc:creator>Barbara Thorand</dc:creator>
<dc:creator>Annette Peters</dc:creator>
<dc:creator>Hugh Tunstall-Pedoe</dc:creator>
<dc:creator>Frank Kee</dc:creator>
<dc:creator>Veikko Salomaa</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Kari Kuulasmaa</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:creator>Christoph Waldeyer</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:creator>BiomarCaRE Investigators</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol- or Apolipoprotein B-Related Risk of Coronary Heart Disease</dc:title>
<dc:identifier>pmid:38960510</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.050</dc:identifier>
</item>
<item>
<title>Bempedoic Acid Falls in Line</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):163-164. doi: 10.1016/j.jacc.2024.05.027.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960509</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.027>10.1016/j.jacc.2024.05.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960509</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Maya S Safarova</dc:creator>
<dc:creator>Patrick M Moriarty</dc:creator>
<dc:creator>Iftikhar J Kullo</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:creator>Eugenia Gianos</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bempedoic Acid Falls in Line</dc:title>
<dc:identifier>pmid:38960509</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.027</dc:identifier>
</item>
<item>
<title>Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38960508/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 9;84(2):152-162. doi: 10.1016/j.jacc.2024.04.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether the relationship between LDL-C lowering and cardiovascular benefit achieved with bempedoic acid resembles that observed with statins when standardized per unit change in LDL-C.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To compare the treatment effect of bempedoic acid with statins, the methodology of the Cholesterol Treatment Trialists' Collaboration (CTTC) was applied to outcomes among the 13,970 patients enrolled in the CLEAR Outcomes trial. The CTTC endpoint of "major vascular event" was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal stroke, or coronary revascularization. HRs for CTTC-defined endpoints were normalized to 1 mmol/L differences in LDL-C levels between bempedoic acid and placebo groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A first major vascular event occurred in 703 (10.1%) patients in the bempedoic acid group and 816 (11.7%) patients in the placebo group (HR: 0.85; 95% CI: 0.77-0.94). When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis. Normalized risk reductions were similar for bempedoic acid and statins for the endpoints of major coronary events, nonfatal myocardial infarction, and coronary revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38960508/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38960508</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.048>10.1016/j.jacc.2024.04.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38960508</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:creator>William J Sasiela</dc:creator>
<dc:creator>Tariq Haddad</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Na Li</dc:creator>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Denise Mason</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs</dc:title>
<dc:identifier>pmid:38960508</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.048</dc:identifier>
</item>
<item>
<title>The germline coordinates mitokine signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38959891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>The ability of mitochondria to coordinate stress responses across tissues is critical for health. In C. elegans, neurons experiencing mitochondrial stress elicit an inter-tissue signaling pathway through the release of mitokine signals, such as serotonin or the Wnt ligand EGL-20, which activate the mitochondrial unfolded protein response (UPR^(MT)) in the periphery to promote organismal health and lifespan. We find that germline mitochondria play a surprising role in neuron-to-periphery UPR^(MT)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 26:S0092-8674(24)00650-0. doi: 10.1016/j.cell.2024.06.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ability of mitochondria to coordinate stress responses across tissues is critical for health. In C. elegans, neurons experiencing mitochondrial stress elicit an inter-tissue signaling pathway through the release of mitokine signals, such as serotonin or the Wnt ligand EGL-20, which activate the mitochondrial unfolded protein response (UPR<sup>MT</sup>) in the periphery to promote organismal health and lifespan. We find that germline mitochondria play a surprising role in neuron-to-periphery UPR<sup>MT</sup> signaling. Specifically, we find that germline mitochondria signal downstream of neuronal mitokines, Wnt and serotonin, and upstream of lipid metabolic pathways in the periphery to regulate UPR<sup>MT</sup> activation. We also find that the germline tissue itself is essential for UPR<sup>MT</sup> signaling. We propose that the germline has a central signaling role in coordinating mitochondrial stress responses across tissues, and germline mitochondria play a defining role in this coordination because of their inherent roles in germline integrity and inter-tissue signaling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38959891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38959891</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.010>10.1016/j.cell.2024.06.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38959891</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Koning Shen</dc:creator>
<dc:creator>Jenni Durieux</dc:creator>
<dc:creator>Cesar G Mena</dc:creator>
<dc:creator>Brant M Webster</dc:creator>
<dc:creator>C Kimberly Tsui</dc:creator>
<dc:creator>Hanlin Zhang</dc:creator>
<dc:creator>Larry Joe</dc:creator>
<dc:creator>Kristen M Berendzen</dc:creator>
<dc:creator>Andrew Dillin</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The germline coordinates mitokine signaling</dc:title>
<dc:identifier>pmid:38959891</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.010</dc:identifier>
</item>
<item>
<title>Loss of transient receptor potential channel 5 causes obesity and postpartum depression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38959890/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>Hypothalamic neural circuits regulate instinctive behaviors such as food seeking, the fight/flight response, socialization, and maternal care. Here, we identified microdeletions on chromosome Xq23 disrupting the brain-expressed transient receptor potential (TRP) channel 5 (TRPC5). This family of channels detects sensory stimuli and converts them into electrical signals interpretable by the brain. Male TRPC5 deletion carriers exhibited food seeking, obesity, anxiety, and autism, which were...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 28:S0092-8674(24)00641-X. doi: 10.1016/j.cell.2024.06.001. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hypothalamic neural circuits regulate instinctive behaviors such as food seeking, the fight/flight response, socialization, and maternal care. Here, we identified microdeletions on chromosome Xq23 disrupting the brain-expressed transient receptor potential (TRP) channel 5 (TRPC5). This family of channels detects sensory stimuli and converts them into electrical signals interpretable by the brain. Male TRPC5 deletion carriers exhibited food seeking, obesity, anxiety, and autism, which were recapitulated in knockin male mice harboring a human loss-of-function TRPC5 mutation. Women carrying TRPC5 deletions had severe postpartum depression. As mothers, female knockin mice exhibited anhedonia and depression-like behavior with impaired care of offspring. Deletion of Trpc5 from oxytocin neurons in the hypothalamic paraventricular nucleus caused obesity in both sexes and postpartum depressive behavior in females, while Trpc5 overexpression in oxytocin neurons in knock-in mice reversed these phenotypes. We demonstrate that TRPC5 plays a pivotal role in mediating innate human behaviors fundamental to survival, including food seeking and maternal care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38959890/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38959890</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.001>10.1016/j.cell.2024.06.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38959890</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yongxiang Li</dc:creator>
<dc:creator>Tessa M Cacciottolo</dc:creator>
<dc:creator>Na Yin</dc:creator>
<dc:creator>Yang He</dc:creator>
<dc:creator>Hesong Liu</dc:creator>
<dc:creator>Hailan Liu</dc:creator>
<dc:creator>Yuxue Yang</dc:creator>
<dc:creator>Elana Henning</dc:creator>
<dc:creator>Julia M Keogh</dc:creator>
<dc:creator>Katherine Lawler</dc:creator>
<dc:creator>Edson Mendes de Oliveira</dc:creator>
<dc:creator>Eugene J Gardner</dc:creator>
<dc:creator>Katherine A Kentistou</dc:creator>
<dc:creator>Panayiotis Laouris</dc:creator>
<dc:creator>Rebecca Bounds</dc:creator>
<dc:creator>Ken K Ong</dc:creator>
<dc:creator>John R B Perry</dc:creator>
<dc:creator>Inês Barroso</dc:creator>
<dc:creator>Longlong Tu</dc:creator>
<dc:creator>Jonathan C Bean</dc:creator>
<dc:creator>Meng Yu</dc:creator>
<dc:creator>Kristine M Conde</dc:creator>
<dc:creator>Mengjie Wang</dc:creator>
<dc:creator>Olivia Ginnard</dc:creator>
<dc:creator>Xing Fang</dc:creator>
<dc:creator>Lydia Tong</dc:creator>
<dc:creator>Junying Han</dc:creator>
<dc:creator>Tia Darwich</dc:creator>
<dc:creator>Kevin W Williams</dc:creator>
<dc:creator>Yongjie Yang</dc:creator>
<dc:creator>Chunmei Wang</dc:creator>
<dc:creator>Shelagh Joss</dc:creator>
<dc:creator>Helen V Firth</dc:creator>
<dc:creator>Yong Xu</dc:creator>
<dc:creator>I Sadaf Farooqi</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Loss of transient receptor potential channel 5 causes obesity and postpartum depression</dc:title>
<dc:identifier>pmid:38959890</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.001</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38958989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this trial, lerodalcibep, a novel anti-PCSK9 small binding protein, dosed monthly and stable at ambient temperatures significantly reduced LDL-C in patients with CVD or at high risk of atherosclerotic cardiovascular disease with a safety profile similar to placebo. These results support long-term use of lerodalcibep in patients with CVD or at high risk of CVD who are unable to achieve adequate LDL-C reduction while receiving maximal tolerated statins alone.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 3. doi: 10.1001/jamacardio.2024.1659. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Recent changes in national and international lipid guidelines for reducing cardiovascular events recommend additional drugs, greater reductions, and lower targets for low-density lipoprotein cholesterol (LDL-C) if not attained with statins. The achievement of these targets with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has not yet been evaluated in a randomized clinical trial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the 52-week safety and efficacy of lerodalcibep, a small anti-PCSK9-binding protein, in patients with cardiovascular disease (CVD) or who are at very high or high risk of CVD and requiring addition LDL-C-lowering treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a randomized, double-blind, placebo-controlled phase 3 trial. The trial was conducted at 66 clinics in 11 countries between April 23, 2021, and November 15, 2023. Individuals 18 years and older taking maximally tolerated statin therapy with LDL-C of 70 mg/dL or greater with CVD or 100 mg/dL or greater if at high risk of CVD were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomized 2:1 to monthly 1.2-mL subcutaneous lerodalcibep, 300 mg, or placebo for 52 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The safety analysis included all randomized patients. The co-primary efficacy end points were percent change from baseline in LDL-C at week 52 and the mean of weeks 50 and 52. Secondary efficacy outcomes included additional lipid apolipoprotein measures and achievement of guideline-recommended LDL-C targets.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 922 randomized participants (mean [range] age, 64.5 [27-87] years; 414 [44.9%] female; mean [SD] baseline LDL-C, 116.2 [43.5] mg/dL), 811 (88%) completed the trial. The mean (SE) placebo-adjusted reduction in LDL-C with lerodalcibep by modified intention-to-treat (mITT) analysis was 56.2% (2.2%) at week 52 and 62.7% (1.9%) for the mean of weeks 50 and 52; 49.7% (2.4%) and 55.3% (2.2%) by ITT with imputation using a washout model, and 60.3% (2.3%) and 65.9% (1.9%) by per-protocol analysis at week 52 and the mean of weeks 50 and 52, respectively (P &lt; .001 for all). With lerodalcibep, 555 of 615 participants (90%) achieved both a reduction in LDL-C of 50% or greater and recommended LDL-C targets during the study. Treatment-emergent adverse events were similar between lerodalcibep and placebo, except for injection site reactions. These occurred in 42 of 613 participants receiving lerodalcibep (6.9%) compared to 1 of 307 receiving placebo (0.3%), were graded mild or moderate, and did not result in higher discontinuation of treatment, at 26 of 613 (4.2%) and 14 of 307 (4.6%), respectively. Sporadic in vitro antidrug antibodies were detected, which had no impact on free PCSK9 or LDL-C-lowering efficacy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this trial, lerodalcibep, a novel anti-PCSK9 small binding protein, dosed monthly and stable at ambient temperatures significantly reduced LDL-C in patients with CVD or at high risk of atherosclerotic cardiovascular disease with a safety profile similar to placebo. These results support long-term use of lerodalcibep in patients with CVD or at high risk of CVD who are unable to achieve adequate LDL-C reduction while receiving maximal tolerated statins alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04806893.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38958989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38958989</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1659>10.1001/jamacardio.2024.1659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38958989</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Eric Q Klug</dc:creator>
<dc:creator>Sara Llerena</dc:creator>
<dc:creator>Lesley J Burgess</dc:creator>
<dc:creator>Nyda Fourie</dc:creator>
<dc:creator>Russell Scott</dc:creator>
<dc:creator>Jeff Vest</dc:creator>
<dc:creator>Kate Caldwell</dc:creator>
<dc:creator>David Kallend</dc:creator>
<dc:creator>Evan A Stein</dc:creator>
<dc:creator>LIBERATE-HR Investigators</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38958989</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1659</dc:identifier>
</item>
<item>
<title>Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38958943/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this case-control study with detailed clinical data and stored plasma samples available in the first trimester, an aptamer-based proteomics panel did not meaningfully add to predictive utility over and above clinical and demographic factors that are routinely available.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 3. doi: 10.1001/jamacardio.2024.1621. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: There is no consensus regarding the best method for prediction of hypertensive disorders of pregnancy (HDP), including gestational hypertension and preeclampsia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine predictive ability in early pregnancy of large-scale proteomics for prediction of HDP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a nested case-control study, conducted in 2022 to 2023, using clinical data and plasma samples collected between 2010 and 2013 during the first trimester, with follow-up until pregnancy outcome. This multicenter observational study took place at 8 academic medical centers in the US. Nulliparous individuals during first-trimester clinical visits were included. Participants with HDP were selected as cases; controls were selected from those who delivered at or after 37 weeks without any HDP, preterm birth, or small-for-gestational-age infant. Age, self-reported race and ethnicity, body mass index, diabetes, health insurance, and fetal sex were available covariates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Proteomics using an aptamer-based assay that included 6481 unique human proteins was performed on stored plasma. Covariates were used in predictive models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Prediction models were developed using the elastic net, and analyses were performed on a randomly partitioned training dataset comprising 80% of study participants, with the remaining 20% used as an independent testing dataset. Primary measure of predictive performance was area under the receiver operating characteristic curve (AUC).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 753 HDP cases and 1097 controls with a mean (SD) age of 26.9 (5.5) years. Maternal race and ethnicity were 51 Asian (2.8%), 275 non-Hispanic Black (14.9%), 275 Hispanic (14.9%), 1161 non-Hispanic White (62.8% ), and 88 recorded as other (4.8%), which included those who did not identify according to these designations. The elastic net model, allowing for forced inclusion of prespecified covariates, was used to adjust protein-based models for clinical and demographic variables. Under this approach, no proteins were selected to augment the clinical and demographic covariates. The predictive performance of the resulting model was modest, with a training set AUC of 0.64 (95% CI, 0.61-0.67) and a test set AUC of 0.62 (95% CI, 0.56-0.68). Further adjustment for study site yielded only minimal changes in AUCs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this case-control study with detailed clinical data and stored plasma samples available in the first trimester, an aptamer-based proteomics panel did not meaningfully add to predictive utility over and above clinical and demographic factors that are routinely available.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38958943/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38958943</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1621>10.1001/jamacardio.2024.1621</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38958943</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Philip Greenland</dc:creator>
<dc:creator>Mark R Segal</dc:creator>
<dc:creator>Rebecca B McNeil</dc:creator>
<dc:creator>Corette B Parker</dc:creator>
<dc:creator>Victoria L Pemberton</dc:creator>
<dc:creator>William A Grobman</dc:creator>
<dc:creator>Robert M Silver</dc:creator>
<dc:creator>Hyagriv N Simhan</dc:creator>
<dc:creator>George R Saade</dc:creator>
<dc:creator>Peter Ganz</dc:creator>
<dc:creator>Priya Mehta</dc:creator>
<dc:creator>Janet M Catov</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Jasmina Varagic</dc:creator>
<dc:creator>Sadiya S Khan</dc:creator>
<dc:creator>Samuel Parry</dc:creator>
<dc:creator>Uma M Reddy</dc:creator>
<dc:creator>Brian M Mercer</dc:creator>
<dc:creator>Ronald J Wapner</dc:creator>
<dc:creator>David M Haas</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Large-Scale Proteomics in Early Pregnancy and Hypertensive Disorders of Pregnancy</dc:title>
<dc:identifier>pmid:38958943</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1621</dc:identifier>
</item>
<item>
<title>Incidental Complication From a Left Atrial Appendage Device</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38958942/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jul 3. doi: 10.1001/jamacardio.2024.1571. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38958942/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38958942</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1571>10.1001/jamacardio.2024.1571</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38958942</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Rimmy Garg</dc:creator>
<dc:creator>Sudhir Mungee</dc:creator>
<dc:creator>Rebecca Baumann</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Incidental Complication From a Left Atrial Appendage Device</dc:title>
<dc:identifier>pmid:38958942</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1571</dc:identifier>
</item>
<item>
<title>Forme fruste unicuspid aortic valves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38958404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 3:ehae432. doi: 10.1093/eurheartj/ehae432. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38958404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38958404</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae432>10.1093/eurheartj/ehae432</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38958404</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jama Jahanyar</dc:creator>
<dc:creator>Laurent de Kerchove</dc:creator>
<dc:creator>Gebrine El Khoury</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Forme fruste unicuspid aortic valves</dc:title>
<dc:identifier>pmid:38958404</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae432</dc:identifier>
</item>
<item>
<title>mTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38957991/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CCM3 is critical for maintaining blood-brain barrier integrity and CCM3 loss-induced mTORC1 signaling in brain EPCs initiates and facilitates CCM pathogenesis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 3. doi: 10.1161/CIRCRESAHA.123.324015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cerebral vascular malformations (CCMs) are primarily found within the brain, where they result in increased risk for stroke, seizures, and focal neurological deficits. The unique feature of the brain vasculature is the blood-brain barrier formed by the brain neurovascular unit. Recent studies suggest that loss of CCM genes causes disruptions of blood-brain barrier integrity as the inciting events for CCM development. CCM lesions are proposed to be initially derived from a single clonal expansion of a subset of angiogenic venous capillary endothelial cells (ECs) and respective resident endothelial progenitor cells (EPCs). However, the critical signaling events in the subclass of brain ECs/EPCs for CCM lesion initiation and progression are unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Brain EC-specific CCM3-deficient (<i>Pdcd10</i><sup>BECKO</sup>) mice were generated by crossing <i>Pdcd10</i><sup><i>fl/fl</i></sup> mice with <i>Mfsd2a</i>-CreER<sup>T2</sup> mice. Single-cell RNA-sequencing analyses were performed by the chromium single-cell platform (10× genomics). Cell clusters were annotated into EC subtypes based on visual inspection and GO analyses. Cerebral vessels were visualized by 2-photon in vivo imaging and tissue immunofluorescence analyses. Regulation of mTOR (mechanistic target of rapamycin) signaling by CCM3 and Cav1 (caveolin-1) was performed by cell biology and biochemical approaches.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-cell RNA-sequencing analyses from P10 <i>Pdcd1</i>0<sup>BECKO</sup> mice harboring visible CCM lesions identified upregulated CCM lesion signature and mitotic EC clusters but decreased blood-brain barrier-associated EC clusters. However, a unique EPC cluster with high expression levels of stem cell markers enriched with mTOR signaling was identified from early stages of the P6 <i>Pdcd1</i>0<sup>BECKO</sup> brain. Indeed, mTOR signaling was upregulated in both mouse and human CCM lesions. Genetic deficiency of Raptor (regulatory-associated protein of mTOR), but not of Rictor (rapamycin-insensitive companion of mTOR), prevented CCM lesion formation in the <i>Pdcd10</i><sup>BECKO</sup> model. Importantly, the mTORC1 (mTOR complex 1) pharmacological inhibitor rapamycin suppressed EPC proliferation and ameliorated CCM pathogenesis in <i>Pdcd10</i><sup>BECKO</sup> mice. Mechanistic studies suggested that Cav1/caveolae increased in CCM3-depleted EPC-mediated intracellular trafficking and complex formation of the mTORC1 signaling proteins.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CCM3 is critical for maintaining blood-brain barrier integrity and CCM3 loss-induced mTORC1 signaling in brain EPCs initiates and facilitates CCM pathogenesis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38957991/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38957991</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324015>10.1161/CIRCRESAHA.123.324015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38957991</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Wang Min</dc:creator>
<dc:creator>Lingfeng Qin</dc:creator>
<dc:creator>Haifeng Zhang</dc:creator>
<dc:creator>Francesc López-Giráldez</dc:creator>
<dc:creator>Ning Jiang</dc:creator>
<dc:creator>Yeaji Kim</dc:creator>
<dc:creator>Varsha K Mohan</dc:creator>
<dc:creator>Minhong Su</dc:creator>
<dc:creator>Katie N Murray</dc:creator>
<dc:creator>Jaime Grutzendler</dc:creator>
<dc:creator>Jenny Huanjiao Zhou</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>mTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis</dc:title>
<dc:identifier>pmid:38957991</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324015</dc:identifier>
</item>
<item>
<title>Cardiomyocyte PANX1 Controls Glycolysis and Neutrophil Recruitment in Hypertrophy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38957990/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Together, these data demonstrate that PANX1 deficiency in cardiomyocytes increases glycolytic metabolism and protects against cardiac hypertrophy in nonischemic heart failure at least in part by reducing immune cell recruitment. Our study implies PANX1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in patients with heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 3. doi: 10.1161/CIRCRESAHA.124.324650. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: PANX1 (pannexin 1), a ubiquitously expressed ATP release membrane channel, has been shown to play a role in inflammation, blood pressure regulation, and myocardial infarction. However, the possible role of PANX1 in cardiomyocytes in the progression of heart failure has not yet been investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHOD: We generated a novel mouse line with constitutive deletion of PANX1 in cardiomyocytes (Panx1<sup>MyHC6</sup>).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: PANX1 deletion in cardiomyocytes had no effect on unstressed heart function but increased the glycolytic metabolism and resulting glycolytic ATP production, with a concurrent decrease in oxidative phosphorylation, both in vivo and in vitro. In vitro, treatment of H9c2 cardiomyocytes with isoproterenol led to PANX1-dependent release of ATP and Yo-Pro-1 uptake, as assessed by pharmacological blockade with spironolactone and siRNA-mediated knockdown of PANX1. To investigate nonischemic heart failure and the preceding cardiac hypertrophy, we administered isoproterenol, and we demonstrated that Panx1<sup>MyHC6</sup> mice were protected from systolic and diastolic left ventricle volume increases as a result of cardiomyocyte hypertrophy. Moreover, we found that Panx1<sup>MyHC6</sup> mice showed decreased isoproterenol-induced recruitment of immune cells (CD45<sup>+</sup>), particularly neutrophils (CD11b<sup>+</sup>, Ly6g<sup>+</sup>), to the myocardium.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Together, these data demonstrate that PANX1 deficiency in cardiomyocytes increases glycolytic metabolism and protects against cardiac hypertrophy in nonischemic heart failure at least in part by reducing immune cell recruitment. Our study implies PANX1 channel inhibition as a therapeutic approach to ameliorate cardiac dysfunction in patients with heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38957990/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38957990</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324650>10.1161/CIRCRESAHA.124.324650</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38957990</guid>
<pubDate>Wed, 03 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Caitlin M Pavelec</dc:creator>
<dc:creator>Alexander P Young</dc:creator>
<dc:creator>Hannah L Luviano</dc:creator>
<dc:creator>Emily E Orrell</dc:creator>
<dc:creator>Anna Szagdaj</dc:creator>
<dc:creator>Nabin Poudel</dc:creator>
<dc:creator>Abigail G Wolpe</dc:creator>
<dc:creator>Samantha H Thomas</dc:creator>
<dc:creator>Scott Yeudall</dc:creator>
<dc:creator>Clint M Upchurch</dc:creator>
<dc:creator>Mark D Okusa</dc:creator>
<dc:creator>Brant E Isakson</dc:creator>
<dc:creator>Matthew J Wolf</dc:creator>
<dc:creator>Norbert Leitinger</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiomyocyte PANX1 Controls Glycolysis and Neutrophil Recruitment in Hypertrophy</dc:title>
<dc:identifier>pmid:38957990</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324650</dc:identifier>
</item>
<item>
<title>Private Equity in Cardiovascular Practice: Solution or Symptom</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38955291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240704160945&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 21:S0735-1097(24)07610-1. doi: 10.1016/j.jacc.2024.06.012. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38955291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240704160945&v=2.18.0.post9+e462414">38955291</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.012>10.1016/j.jacc.2024.06.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38955291</guid>
<pubDate>Tue, 02 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Edward T A Fry</dc:creator>
<dc:date>2024-07-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Private Equity in Cardiovascular Practice: Solution or Symptom</dc:title>
<dc:identifier>pmid:38955291</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.012</dc:identifier>
</item>





























</channel>
</rss>